The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Selpercatinib for RET-Altered Cancers: Selective RET Kinase Inhibitor

Highly selective RET tyrosine kinase inhibitor for medullary thyroid cancer with RET mutations and non-small cell lung cancer with RET fusions

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Selpercatinib for RET-Altered Cancers: Selective RET Kinase Inhibitor?

Selpercatinib is highly selective potent oral inhibitor of RET tyrosine kinase with picomolar potency against RET.

RET alterations include activating point mutations and chromosomal rearrangements with diverse fusion partners.

FDA approvals include RET fusion-positive NSCLC, RET fusion-positive thyroid cancer, RET-mutant medullary thyroid cancer in adults and pediatrics.

Selectivity for RET over other kinases provides superior tolerability compared to multikinase inhibitors.

RET fusion partners in NSCLC include KIF5B, CCDC6, NCOA4 and others identified through molecular profiling.

Symptoms

Hypertension is common adverse effect requiring proactive antihypertensive management.
Hepatotoxicity with elevated transaminases requires monitoring and dose modification when significant.
QT interval prolongation requires baseline and serial ECG monitoring with electrolyte management.
Hemorrhage risk including major bleeding events requires careful monitoring particularly in patients with risk factors.
Edema, fatigue, dry mouth, decreased platelet count are common adverse effects.

Risk Factors

MEN2A and MEN2B syndromes with germline RET mutations cause medullary thyroid cancer with high penetrance.
Sporadic medullary thyroid cancer with somatic RET M918T mutation occurs in approximately 50% of cases.
RET fusions in NSCLC occur in approximately 1-2% with implications for molecular profiling all advanced NSCLC.
Pre-existing hypertension, cardiac disease, hepatic dysfunction require careful monitoring during therapy.
Concurrent strong CYP3A4 inhibitors require dose adjustments given metabolic interactions.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Advanced or metastatic NSCLC, thyroid cancer or other solid tumors warrant comprehensive molecular profiling including RET fusion testing.
  • Confirmed RET alteration positive cancer represents indication for selpercatinib targeted therapy consideration.
  • Severe hypertensive crisis, hepatotoxicity with significant transaminase elevation, QT prolongation require urgent evaluation.
  • Major bleeding events, intracranial hemorrhage warrant immediate evaluation and treatment discontinuation.
  • Multidisciplinary care including medical oncology, cardiology, hepatology, molecular pathology optimizes outcomes.

Treatment Methods

01
Selpercatinib 160 mg orally twice daily continuous dosing represents standard regimen with weight-based dosing in pediatrics.
02
Aggressive blood pressure management with antihypertensive medications targeting goals less than 140/90 mmHg.
03
Liver function monitoring at baseline, every 2 weeks for first 3 months, then monthly with dose modification for significant elevation.
04
QT interval monitoring with baseline and serial ECGs, electrolyte management, avoiding QT-prolonging medications.
05
Comprehensive supportive care including hypertension management, hepatic monitoring, ECG surveillance, bleeding precautions, drug interaction review with attention to CYP3A4 modulators, multidisciplinary monitoring, and management of resistance through molecular profiling at progression with consideration of next-generation RET inhibitors when available optimizes long-term outcomes for patients with RET-altered cancers.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.